L. Pina Vegas

Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database.

E. Sbidian, L. Penso, P. Claudepierre, 2020, Rheumatology.

Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)

E. Sbidian, P. Claudepierre, Léa Hoisnard, 2022, RMD Open.

Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort

A. Luciani, S. Ferkal, P. Goupille, 2021, Rheumatology.

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

M. Zureik, E. Sbidian, Léa Hoisnard, 2022, Annals of the Rheumatic Diseases.

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study

E. Sbidian, L. Penso, P. Claudepierre, 2021, Rheumatology.

Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.

M. Zureik, A. Weill, L. Penso, 2021, JAMA dermatology.

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.

L. Penso, P. Claudepierre, L. Pina Vegas, 2022, JAMA dermatology.